Enhance human health and improve healthcare delivery by providing novel and actionable personalized medical information to patients and physicians;
Lead the global molecular diagnostics market by providing a continuous stream of novel and effective molecular diagnostic tests to improve patient health management and facilitate clinical decisions.
To be the leader in developing blood-based biomarkers as a basis for molecular diagnostic tests and creating a systems biology database that enables personalized medicine and health management
GeneNews Limited (formerly ChondroGene Limited) was formed in 1998 by its two founders; Dr. K. Wayne Marshall, a noted orthopaedic surgeon and knee specialist and Dr. C.C. Liew, an internationally recognized leader in the area of tissue-specific functional genomics.
GeneNews was founded to focus on the identification of novel therapeutic targets for a single disease, osteoarthritis. At that time, the company was interested in the gene expression of cartilage cells called chondrocytes, hence the name ChondroGene. The goal was to examine how the tissues of the joint function in different stages of osteoarthritis; from normal joints, to moderately diseased joints, all the way to severe osteoarthritis which can be treated only by total joint replacement. Genenews’ work on Osteroarthritis led to two collaborations with Pfizer Inc.
Going forward, our ability to generate biomarker content based on the Sentinel Principle and Discovery Funnel will enable development of a broad range of Sentry tests and related applications. These gene-based tests and the genomic information gained from our discovery pipeline will provide a continuing stream of novel information or "news" across a broad range of diseases and clinical questions. Given these considerations, the company decided it was appropriate to change its’ name to GeneNews.
GeneNews Limited is an Ontario incorporated company headquartered in Toronto. The active business and operations are conducted through a wholly-owned subsidiary, GeneNews Corporation. GeneNews has a single class of common shares that are listed for trading on the TSX Exchange under the stock symbol "GEN".